Pratibha Sahu

Cancer is a major global cause of death that requires new approaches to treatment outside the use of traditional chemotherapy, radiotherapy, and surgery. Nanomedicine, based on the application of nanoparticles (NPs) to targeted drug delivery, offers an exciting area of research for increased therapeutic benefits while reducing side effects. In this review, developments in nanotechnology-based drug delivery systems (DDSs) are discussed, focusing on their value in transcending multidrug resistance (MDR), improving bioavailability, and increasing the specificity of treatment. Several NP-based systems, such as liposomes, polymeric NPs, metal NPs, and quantum dots, are analyzed with respect to cancer therapy. Additionally, this paper addresses issues with clinical translation, including biocompatibility, toxicity, and regulatory issues. At last, upcoming trends and directions of future studies to optimize NP-based cancer treatments are presented.

Patients who are suffering from illnesses that influence the central nervous system (CNS) struggle with getting medicine because of the presence of two barriers: the blood-cerebrospinal fluid boundary and the intrinsic blood-cerebrum obastruction (BBB). Both of these barriers make it hard to safely give prescription. There are various neurological conditions that are routinely perceived, including Alzheimer's disease, frontotemporal dementia, amyotrophic parallel sclerosis, Parkinson's disease, and Huntington's disease, to give some examples. In addition to these disorders, there are some that can affect the neurological system. Nanotechnology in drug conveyance systems is one therapy strategy that has the possibility to be powerful in the treatment of specific ailments. This is because nanotechnology has the capacity to control the distribution of drugs. To conquer the problems that have been presented and making progress in the conveyance of medications to the central nervous system, various approaches have been created to be successful. This research was completed determined to cast light on late advancements in the field of nanotherapeutics research and the possible consequences of these advancements in the treatment of illnesses that disable the central nervous system. The research was completed with the target of shedding light on these advancements. Another subject that is investigated is the challenges that are experienced while endeavoring to bring nanomedicine from the research facility to the bedside with the end goal of clinical application.